Livzon Pharmaceutical Group Inc., ( China (Mainland))

Livzon Pharmaceutical Group Inc., founded in the year of 1985, has already established itself as one of the leading pharmaceutical company in China. In 1993, Livzon became the first local pharmaceutical company to list both A and B shares, with multifold turnover in development, manufacture, and marketing of diversified pharmaceutical products. After a consistent growth, it possesses a total capital of 2.2 billion RMB inclusive of 24 controlled subsidiaries and joint ventures.
      
With 9 affiliated plants equipped by advanced facilities, the dynamic production chain efficiently operates to manufacture APIs, finished dosage forms, diagnostic agents and bioactive material, characterized by know-how of fermentation, synthesis, gene recombination, biological extraction, and traditional Chinese medicines, with more than 300 items therapeutically grouped as gastrointestinal, anti-infectious (antibacterial, antiviral), cardiovascular, anti-cancer, immunomodulant, reproductive, neurological, urological, dermatological and pediatric agents.

Meanwhile, Livzon possesses 4 Production Bases as leading manufacturer of specialist APIs include fermented antibiotics, sterile cephalosporins, carbapenems, and hypolipemic "Statins". Such as Ceftriaxone Sodium (104376-79-6) , Clindamycin Hydrochloride (21462-39-5) , Clarithromycin (81103-11-9), Roxithromycin (80214-83-1) , etc.
     
There are 38 production lines in compliance with WHO GMP requirements, including some DMFs and EDMFs documentation, as well as USA FDA inspection, COS and COSHER approvals. Benefited from the regulatory compliance, an extensive overseas market is under robust development, with prosperous vision in Canada, Japan, Middle East, South Africa, South East Asia, and West Europe.